ProfileGDS4814 / ILMN_1655608
TitleOvarian cancer xenograft tumor response to trastuzumab and pertuzumab
OrganismHomo sapiens


none trastuzumab pertuzumab trastuzumab and pertuzumab GSM780707 GSM780708 GSM780709 GSM780719 GSM780720 GSM780721 GSM780710 GSM780711 GSM780712 GSM780722 GSM780723 GSM780724 GSM780713 GSM780714 GSM780715 GSM780725 GSM780726 GSM780727 GSM780716 GSM780717 GSM780718 GSM780728 GSM780729 73% 71% 71% 72% 73% 71% 69% 72% 71% 70% 71% 72% 70% 72% 74% 74% 73% 73% 67% 71% 74% 71% 71% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM780707Untreated after 4 days (C1_1)87.314373
GSM780708Untreated after 4 days (C2_1)75.538371
GSM780709Untreated after 4 days (C3_1)78.25771
GSM780719Untreated after 4 days (C1_2)80.601872
GSM780720Untreated after 4 days (C2_2)86.448473
GSM780721Untreated after 4 days (C3_2)76.86171
GSM780710Trastuzumab treated after 4 days (T1_1)71.507369
GSM780711Trastuzumab treated after 4 days (T2_1)83.018672
GSM780712Trastuzumab treated after 4 days (T3_1)78.657971
GSM780722Trastuzumab treated after 4 days (T1_2)74.630470
GSM780723Trastuzumab treated after 4 days (T2_2)79.224271
GSM780724Trastuzumab treated after 4 days (T3_2)79.652672
GSM780713Pertuzumab treated after 4 days (P1_1)74.313270
GSM780714Pertuzumab treated after 4 days (P2_1)82.981572
GSM780715Pertuzumab treated after 4 days (P3_1)90.787274
GSM780725Pertuzumab treated after 4 days (P1_2)89.706874
GSM780726Pertuzumab treated after 4 days (P2_2)87.585973
GSM780727Pertuzumab treated after 4 days (P3_2)84.01873
GSM780716Trastuzumab and Pertuzumab treated after 4 days (TP1_1)63.808767
GSM780717Trastuzumab and Pertuzumab treated after 4 days (TP2_1)76.608271
GSM780718Trastuzumab and Pertuzumab treated after 4 days (TP3_1)90.778774
GSM780728Trastuzumab and Pertuzumab treated after 4 days (TP1_2)78.880871
GSM780729Trastuzumab and Pertuzumab treated after 4 days (TP2_2)78.051571